Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer

NCT01212822 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT01212822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01212822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2011
Completion date
January 3, 2018
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the esophagus, adenocarcinoma of the gastroesophageal junction, diffuse adenocarcinoma of the stomach, intestinal adenocarcinoma of the stomach, mixed adenocarcinoma of the stomach, squamous cell carcinoma of the esophagus, stage ia esophageal cancer, stage ia gastric cancer, stage ib esophageal cancer, stage ib gastric cancer, stage iia esophageal cancer, stage iia gastric cancer, stage iib esophageal cancer, stage iib gastric cancer, stage iiia esophageal cancer, stage iiia gastric cancer, stage iiib esophageal cancer, stage iiib gastric cancer, stage iiic esophageal cancer, stage iiic gastric cancer